BioSpace News Archive

Sol-Gel Technologies, Ltd. announced that TWYNEO®, a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide, 3% for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, is now available for purchase by consumers who obtain a prescription from their physician.

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. announced today that the United States Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) for toripalimab, a PD-1 inhibitor, for the treatment of small cell lung cancer (“SCLC”).

Innovative Neurological Devices is pleased to announce the availability of a no-cost medical device authorization service for patients interested in purchasing the Cervella Cranial Electrotherapy Stimulator™.

Neuvivo today announced that Michael Snyder , PhD, will join the company’s Scientific Advisory Board.

BeyondSpring Inc. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission on April 14, 2022.

Global health services company Cigna Corporation (NYSE:CI) will release its first quarter 2022 financial results on Friday, May 6, 2022, and will host a conference call the same day.

Life Biosciences today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the fourth annual Longevity Leaders World Congress being held on April 26-27, 2022, in London, UK .

Aditxt, Inc., a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC.

TracPatch Health, a leader in wearable data monitoring for musculoskeletal health, announced its TracPatch Knee remote patient monitoring solution has received an Innovative Technology contract in the category of Wearables from Vizient, Inc., the nation’s largest member-driven health care performance improvement company.

The rising prevalence of diseases such as rheumatoid arthritis will add boost to the growth of the global glucosamine market during the forecast period, 2020 to 2030.